Type 1 diabetes is a lifelong autoimmune disease in which the pancreas loses its ability to produce insulin, leading to the accumulation of sugar in the bloodstream. High blood sugar is known as hyperglycemia, and it can even prove fatal if not treated. It is estimated that about 2.1 million Americans have type 1 diabetes. Insulin therapies marketed by Lilly, Novo Nordisk; and Sanofi, to name a few; Sanofi's immune therapy Tzield; CellTrans' cell therapy Lantidra; and AstraZeneca's adjunctive treatment Symlin are some of the FDA-approved treatments for type 1 diabetes. There is no cure yet for this disease.
The company we are profiling today is Lexicon Pharmaceuticals Inc. (LXRX), which is developing an adjunct therapy to insulin for type 1 diabetes in adults.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.